Relief Therapeutics Expands U.S. Commercial Team

Tracy Truong and Kelli Powell Appointed Regional Clinical Specialists for the West and Northeast Regions, Respectively
Seasoned Account Managers Bring Extensive Pharmaceutical Sales Experience in Rare Diseases

GENEVA, SWITZERLAND / ACCESSWIRE / May 23, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced today the appointments, effective May 23, 2022, of Tracy Truong and Kelli Powell, as Regional Clinical Specialists for the West and Northeast Regions, respectively. Both Ms. Truong and Ms. Powell will report directly to Chris Wick, Executive Director and Head of U.S. Sales.

Foto: Accesswire

"As highly accomplished, proven pharmaceutical sales leaders who bring deep expertise from careers spent at top-tier firms including Alexion, Bristol-Myers Squibb, Genzyme, Shire/NPS Pharmaceuticals and others, Tracy and Kelli will be integral members of the Relief commercial team and their appointments reflect our continued commitment to building out our U.S. operations," stated Anthony Kim, Senior Vice President and Head of U.S. Commercial Operations of Relief. "Their passion for serving the needs of patients, coupled with their extensive experience in rare diseases, will enable them to make significant and lasting contributions to the future of our company. We look forward to leveraging their knowledge and industry relationships for the anticipated rollout of PKU GOLIKE^®, the flagship product line of our wholly owned subsidiary, APR Applied Pharma Research, SA (APR), and for the potential launch of ACER-001, for the treatment of Urea Cycle Disorders, in collaboration with Acer Therapeutics, which has an upcoming June 5, 2022 Prescription Drug User Fee Act (PDUFA) date."

Ms. Truong will join Relief from Alexion where, since 2017, she served as a Regional Account Manager promoting Strensiq^®, an enzyme replacement therapy indicated for hypophosphatasia, an ultra-rare genetic disorder. Prior to that, she was a Regional Account Manager at Shire/NPS Pharma representing Gattex^®, indicated for the rare, ultra-orphan disease, short bowel syndrome. Before that, Ms. Truong was a Senior Sales Specialist at UCB, Inc., promoting Cimzia^®, a TNF blocker indicated for Crohn's disease. Earlier in her career, she held sales positions at Bristol-Myers Squibb, Three Rivers/Valeant Pharmaceuticals and AstraZeneca LP. Ms. Truong earned a B.S. in biology from California State University, Long Beach, an MBA from The George L. Graziadio School of Business and Management at Pepperdine University, and a Genetics and Genomics Certificate from Stanford University.